Genetic mechanisms of resistance to targeted KRAS inhibition
Diaz, B. J.; Kops, M.; Bernardo, S.; Schmidt, H.; Grankowsky, E.; Vega, A.; Zhang, C.; Bott, M.; Skamagki, M.; Tomlinson, A.; Vita, N. A.; Katti, A.; Labrecque, M. P.; Aronchik, I.; Singh, M.; Dow, L. E.
Show abstract
KRAS mutations are among the most prevalent oncogenic drivers in non-small cell lung cancer (NSCLC), yet the mechanisms of therapeutic resistance to KRAS inhibitors in these cancers remains poorly understood. Here, we deploy high-throughput CRISPR base editing screens to systematically map resistance mutations to three mechanistically distinct KRAS-targeted therapies, including KRAS-G12C(OFF) inhibitor (adagrasib), RAS(ON) G12C-selective tri-complex inhibitor (RMC-4998), and RAS(ON) multi-selective tri-complex inhibitor (RMC-7977). Using both a saturation Kras tiling approach and cancer-associated mutation library, we identify common and compound-selective second-site resistance mutations in Kras, as well as gain-of-function and loss-of-function variants across cancer-associated genes that rewire signaling networks in a context-dependent manner. Notably, we identify a recurrent missense mutation in capicua (Cic), that promotes resistance to RMC-7977 in vitro and in vivo. Moreover, we show that targeting NF{kappa}B signaling in CIC-mutant cells can resensitize them to RAS pathway inhibition and overcome resistance.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer 97%
- Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2 97%
- The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. 97%
Similar papers in this journal
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 96%
- Non-oncology drugs are a source of previously unappreciated anti-cancer activity 96%
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 95%
Similar papers in this journal
- Quantitative in vivo analyses reveal a complex pharmacogenomic landscape in lung adenocarcinoma 97%
- Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities 97%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.